AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04448522 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional dosage IMRT
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy
Study NCT05131126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet method
Description: This operation consists of fixing a bone graft
Study NCT05131126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different arms exercices
Description: Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation.
Study NCT05131126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different arms exercices
Description: Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation.
Study NCT04081480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valacyclovir
Description: PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
Study NCT00926744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
Study NCT01662466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone cream (0.5mg per gram)
Description: Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
Study NCT01662466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHEA
Description: DHEA 25mg tid
Study NCT01662466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: DHEA 25mg tid
Study NCT01662466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carrier cream without added testosterone in the identical type of pump
Study NCT00855283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN NEO
Description: 20 mg Neostigmine via intranasal and sublingual administration
Study NCT05941143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based intervention
Description: 8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
Study NCT03005743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image based Brachytherapy
Description: MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines \[Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A\]
Study NCT03005743 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional Radiograph based Brachytherapy
Description: The standard conventional radiography based prescription will be according to Manchester system Point A and bladder \& rectum ICRU point dose constraints
Study NCT00819598 — intervention group
Intervention type: PROCEDURE
Intervention: BLOOD PRESSURE MEASURMENT
Description: Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
Study NCT00819598 — intervention group
Intervention type: PROCEDURE
Intervention: BLOOD PRESSURE MEASUREMENT
Description: Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
Study NCT03361969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estetrol
Description: estetrol formulated in tablets
Study NCT03361969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablets
Study NCT04079413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP40071
Description: GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Study NCT04079413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid® Penfill®
Description: NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Study NCT02513498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02513498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02513498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02513498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04089566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nusinersen
Description: Administered as specified in the treatment arm
Study NCT04089566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm
Study NCT02396420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Study NCT04362072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: 25 milligram (mg) tablet
Study NCT02515383 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Complete cognitive debriefing interview
Study NCT02515383 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02515383 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete MDASI questionnaire
Study NCT02499653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Study NCT02499653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.
Study NCT02076893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple syrup suspension
Study NCT01623401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: TR-701 FA 200 mg once daily
Study NCT01353690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC
Description: Cell Treatment
Study NCT01860040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Alkylating antineoplastic agent (Chemotherapy)
Study NCT01860040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Antimetabolite antineoplastic agent (Chemotherapy)
Study NCT01860040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antimetabolite antineoplastic agent (Chemotherapy)
Study NCT00757458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDTA without re-filling
Description: Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
Study NCT00757458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propofol syringe re-filling with propofol containing EDTA
Description: Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
Study NCT00757458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol without EDTA
Description: Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
Study NCT00757458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Re-filling of syringe with propofol without EDTA
Description: Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
Study NCT01669174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01669174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338
Study NCT01190410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
Study NCT01190410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
Study NCT03654716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
Study NCT03654716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
Study NCT01243216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
Study NCT00798668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Supplements
Description: Liquid supplement that provides 12.5% of the subjects total energy requirement.
Study NCT00798668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solid Supplement
Description: Solid supplement that provides 12.5% of the subjects total energy requirement.
Study NCT02905981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol
Description: Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
Study NCT02905981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Study NCT02905981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
Study NCT01063270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin & Rifampin
Description: Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
Study NCT01063270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin + Rifampin along with NdYag Laser treatment
Description: Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
Study NCT02648854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
Study NCT02648854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Description: administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
Study NCT03809767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1003 monoclonal antibody
Description: CS1003 will be administered intravenously every 3 weeks.
Study NCT04149782 — intervention group
Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study NCT01802736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention counselling plus SPP
Study NCT01802736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational intervention counselling plus SPP
Study NCT03189667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel preparation with angioplasty
Description: Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon.
Study NCT03189667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel preparation with angioplasty
Description: Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon.
Study NCT03189667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain balloon angioplasty
Description: Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon.
Study NCT03189667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon angioplasty
Description: Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion.
Study NCT05039814 — intervention group
Intervention type: OTHER
Intervention: postoperative acute kidney injury
Description: patients suffered postoperative acute kidney injury
Study NCT05039814 — intervention group
Intervention type: OTHER
Intervention: none postoperative acute kidney injury
Description: patients did not suffered postoperative acute kidney injury
Study NCT03915431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCS-01
Description: single infusion
Study NCT03915431 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: NCS-01
Description: single infusion
Study NCT03549884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
Study NCT03549884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cord clamping
Description: Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
Study NCT04140253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization
Description: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.
Study NCT04140253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization
Description: Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.
Study NCT03113214 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
Study NCT00461292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
Study NCT00461292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (300U)
Description: botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
Study NCT00461292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
Study NCT00461292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (300U)
Description: Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
Study NCT02759185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC cannabis
Description: Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
Study NCT02759185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High CBD cannabis
Description: Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
Study NCT02759185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD cannabis
Description: Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
Study NCT02759185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cannabis
Description: Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
Study NCT04444284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 1)
Description: Single dose administered intranasally on Day 1
Study NCT04444284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 2)
Description: Single dose administered intranasally on Day 1
Study NCT04444284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered intranasally on Day 1
Study NCT04444284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 3)
Description: Single dose administered intranasally on Day 1
Study NCT00836602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-779788
Description: Oral Solution, Oral, 1 mg, Once daily, 7 days